BK virus (BKV) is an opportunistic pathogen in those with impaired immunity. Viral replication is generally asymptomatic but is able to induce cytopathic alterations in renal cells. If BKV infection is left untreated, it leads to BKV-associated nephropathy (BKVAN) and graft loss. There is scarce experience in the management of BKV infection in kidney transplant recipients living with HIV. We report the successful treatment of BKVAN in an HIV-positive kidney transplant recipient who experienced BKV replication in the immediate post-transplantation period. A change in therapy from calcineurin inhibitor to sirolimus, steroid withdrawal and a short course of an immunomodulatory agent (leflunomide) controlled BKV viremia in the absence of drug side-effects or impairment of graft function.
GathogoENHamzahLHiltonR, et al.
Kidney transplantation in HIV-positive adults: the UK experience. Int J STD AIDS2014;
25: 57–66.
2.
LockeJEGustafsonSMehtaS, et al.
Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg2017;
265: 604–608.
3.
AlfanoGMoriGFontanaF, et al.
Clinical outcome of kidney transplantation in HIV-infected recipients: a retrospective study. Int J STD AIDS2018;
29: 1305–1315.
4.
AlfanoGCappelliGFontanaF, et al.
Kidney disease in HIV infection. J Clin Med2019;
8: 1254.
5.
SawinskiDTrofe-ClarkJ.BK virus nephropathy. Clin J Am Soc Nephrol2018;
13: 1893–1896.
6.
BaekCHKimHYuH, et al.
Risk factors of acute rejection in patients with BK nephropathy after reduction of immunosuppression. Ann Transplant2018;
23: 704–712.
7.
CheungpasitpornWKremersWKLorenzE, et al.
De novo donor-specific antibody following BK nephropathy: the incidence and association with antibody-mediated rejection. Clin Transplant2018;
32: e13194.
8.
JacobiJPrignitzABüttnerM, et al.
BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrol2013;
14: 207.
9.
MoscarelliLCarotiLAntognoliG, et al.
Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transplant2013;
27: 546–554.
10.
SchwarzALinnenweber-HeldSHeimA, et al.
Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation. Transplantation2012;
94: 396–402.
11.
TohmeFAKalilRSThomasCP.Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients. Transpl Infect Dis off Dis2015;
17: 66–72.
12.
PolancoNGonzález MonteEFolgueiraMD, et al.
Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant Proc2015;
47: 57–61.
13.
WojciechowskiDChandranSWebberA, et al.
Mycophenolate mofetil withdrawal with conversion to everolimus to treat BK virus infection in kidney transplant recipients. Transplant Proc2017;
49: 1773–1778.
14.
LeveyASStevensLA.Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis off Dis2010;
55: 622–627.
15.
KellerNDuquennoySConradA, et al.
Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: a multicenter retrospective study. Transpl Infect Dis off Dis2019;
21: e13058.
16.
LiaciniASeamoneMEMuruveDA, et al.
Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation2010;
90: 1450–1457.
17.
PearceELWalshMCCejasPJ, et al.
Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature2009;
460: 103–107.
HerediaAAmorosoADavisC, et al.
Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA2003;
100: 10411–10416.
20.
Di BenedettoFDi SandroSDe RuvoN, et al.
First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation2010;
89: 733–738.
21.
AlfanoGFontanaFMoriG, et al.
Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient. Int J STD AIDS2019;
30: 919–922.
22.
StockPGBarinBHatanoH, et al.
Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant2014;
14: 1136–1141.
23.
SawinskiD.Kidney transplantation for HIV-positive patients. Transplant Rev (Orlando)2017;
31: 42–46.
24.
KnollGAKokoloMBMallickR, et al.
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ2014;
349: g6679.
25.
SantosAHCaseyMJXuerongW, et al.
Association of baseline viral serology and sirolimus regimens with kidney transplant outcomes: a 14-year registry-based cohort study in the United States. Transplantation2017;
101: 377–386.
26.
IsakovaTXieHMessingerS, et al.
Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Am J Transplant off Transplant2013;
13: 100–110.
